HCW Biologics Inc. (HCWB)

USD 0.41

(25.0%)

Market Cap (In USD)

15.65 Million

Revenue (In USD)

2.84 Million

Net Income (In USD)

-24.99 Million

Avg. Volume

17.52 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.276-2.52
PE
-
EPS
-
Beta Value
0.838
ISIN
US40423R1059
CUSIP
40423R105
CIK
1828673
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Hing C. Wong Ph.D.
Employee Count
-
Website
https://www.hcwbiologics.com
Ipo Date
2021-07-20
Details
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.